The value of local treatment in patients with primary, disseminated, multifocal ewing sarcoma (PDMES)

Cancer

Volumn 116, Issue 2, 2010, Pages 443-450

  Haeusler, Julia ^a   Ranft, Andreas ^a   Boelling, Tobias ^a   Gosheger, Georg ^a   Braun Munzinger, Gabriele ^a   Vieth, Volker ^a   Burdach, Stefan ^b   Van Den Berg, Henk ^c   Juergens, Heribert ^a   Dirksen, Uta ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Ewing; High dose chemotherapy; Local therapy; Primary dissemination; Radiotherapy; Surgery

Indexed keywords

BUSULFAN; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; TREOSULFAN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW METASTASIS; BONE METASTASIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED CANCER; DISTANT METASTASIS; DRUG MEGADOSE; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; HUMAN; INTESTINE METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; PANCREAS METASTASIS; PLEURA METASTASIS; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN METASTASIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOTHERAPY, ADJUVANT; SARCOMA, EWING'S;

EID: 75649144053     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24740     Document Type: Article

References (34)

1. Grier HE. The Ewing family of tumors: Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am. 1997;44:991-1004.
2. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial Cancer. Cancer. 1988;61:23-32.
3. Donaldson SS, Torrey M, Link MP, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:125-135.
4. Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant. 1995;15:697-705.
5. Fizazi K, Dohollou N, Blay JY, et al. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol. 1998;16:3736-3743.
6. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18:3108-3114.
7. Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Longterm results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer. 1997;33: 1061-1069.
8. Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85:1646-1654.
9. Sluga M, Windhager R, Lang S, et al. A long-term review of the treatment of patients with Ewing's sarcoma in one institution. Eur J Surg Oncol. 2001;27:569-573.
10. Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol. 1995;13:2796-2804.
11. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998;9: 275-281.
12. Oberlin O, Rey A, Desfachelles AS, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l'Enfant. J Clin Oncol. 2006;24:3997-4002.
13. Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M. Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer. 2007;49:196-198.
14. Rosenthal J, Bolotin E, Shakhnovits M, et al. High-dose therapy with hematopoietic stem cell rescue in patients with poor prognosis Ewing family tumors. Bone Marrow Transplant. 2008;42:311-318.
15. Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from 2 centers of the European Intergroup study EICESS Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St Anna Kinderspital, Vienna, Austria. Ann Oncol. 2000;11:1451-1462.
16. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol. 2003;40:276-287.
17. th. Muenster: EURO-E.W.I.N.G. 99, 2006.
18. Dehner LP. Primitive neuroectodermal tumor and Ewing's sarcoma. Am J Surg Pathol. 1993;17:1-13.
19. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M. MIC2 is a specific marker for Ewing's sarcoma and peripheral neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer. 1991;67: 1886-1893.
20. Fellinger EJ, Garin-Chesa P, Triche TJ, Huvos AG, Rettig WJ. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am J Pathol. 1991;139:317-325.
21. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994;331:294-299.
22. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment - cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008;26:4385-4393.
23. Yock TI, Krailo M, Fryer CJ, et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091 - a report from the Children's Oncology Group. J Clin Oncol. 2006;24: 3838-3843.
24. Shankar AG, Pinkerton CR, Atra A, et al. Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer. 1999;35: 1698-1704.
25. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000;18:4-11.
26. Aparicio J, Munarriz B, Pastor M, et al. Long-term followup and prognostic factors in Ewing's sarcoma. A multivariate analysis of 116 patients from a single institution. Oncology. 1998;55:20-26.
27. Elomaa I, Blomqvist CP, Saeter G, et al. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer. 2000;36: 875-880.
28. Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer. 1990;66:887-893.
29. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poorprognosis Ewing's sarcoma. J Clin Oncol. 1993;11:1482-1488.
30. Ladenstein R, Whelan J, Oberlin O, Weston C, Jurgens H. Multivariate analysis-based risk grouping of Ewing tumours (ET) with extrapulmonary metastatic disease (EPMD): Final results from the EURO-E.W.I.N.G. 99 study [abstract]. Clin Oncol. 2007;25(N18S pt I):541s. Abstract 9562.
31. Gerth HU, Juergens KU, Dirksen U, Gerss J, Schober O, Franzius C. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and followup of patients with Ewing tumors. J Nucl Med. 2007;48: 1932-1939.
32. Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med. 2000;27:1305-1311.
33. Franzius C, Hotfilder M, Poremba C, et al. Successful highresolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model. Eur J Nucl Med Mol Imaging. 2006;33: 1432-1441.
34. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828-8834.